Does the media prefer DNA or TWST?

In the previous week, Twist Bioscience had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 11 mentions for Twist Bioscience and 10 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.46 beat Ginkgo Bioworks' score of 0.33 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Twist Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNA or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to Ginkgo Bioworks' net margin of -259.96%. Fortrea's return on equity of 10.72% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% Fortrea -3.18% 10.72% 2.17%

Does the media refer more to DNA or FTRE?

In the previous week, Ginkgo Bioworks had 3 more articles in the media than Fortrea. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 7 mentions for Fortrea. Fortrea's average media sentiment score of 0.37 beat Ginkgo Bioworks' score of 0.33 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DNA or MRVI?

In the previous week, Ginkgo Bioworks had 7 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.60 beat Ginkgo Bioworks' score of 0.33 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLFS or DNA?

In the previous week, Ginkgo Bioworks had 7 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 3 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.85 beat Ginkgo Bioworks' score of 0.33 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ALMR or DNA?

In the previous week, Ginkgo Bioworks had 4 more articles in the media than Alamar Biosciences. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 6 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.41 beat Ginkgo Bioworks' score of 0.33 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ginkgo Bioworks 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Ginkgo Bioworks (DNA) Competitors

$11.72 +0.19 (+1.61%)

Closing price 03:59 PM Eastern

Extended Trading

$11.65 -0.06 (-0.55%)

As of 07:46 PM Eastern

Compare

DNA vs. TWST, FTRE, MRVI, BLFS, and ALMR

Should you buy Ginkgo Bioworks stock or one of its competitors? Ginkgo Bioworks's main competitors and comparable companies include Twist Bioscience (TWST), Fortrea (FTRE), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), and Alamar Biosciences (ALMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Ginkgo Bioworks (NYSE:DNA) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Twist Bioscience has a net margin of -31.66% compared to Ginkgo Bioworks' net margin of -259.96%. Twist Bioscience's return on equity of -28.64% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Ginkgo Bioworks has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 3.1% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ginkgo Bioworks presently has a consensus price target of $7.00, suggesting a potential downside of 39.44%. Twist Bioscience has a consensus price target of $143.67, suggesting a potential downside of 3.03%. Given Twist Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Twist Bioscience is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Twist Bioscience	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	4.57	-$312.76M	-$5.01	N/A
Twist Bioscience	$376.57M	24.67	-$77.67M	-$2.22	N/A

In the previous week, Twist Bioscience had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 11 mentions for Twist Bioscience and 10 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.46 beat Ginkgo Bioworks' score of 0.33 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Twist Bioscience	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Twist Bioscience beats Ginkgo Bioworks on 13 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Fortrea?

Ginkgo Bioworks (NYSE:DNA) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 0.7% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ginkgo Bioworks had 3 more articles in the media than Fortrea. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 7 mentions for Fortrea. Fortrea's average media sentiment score of 0.37 beat Ginkgo Bioworks' score of 0.33 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ginkgo Bioworks has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	4.57	-$312.76M	-$5.01	N/A
Fortrea	$2.68B	0.76	-$986.20M	-$0.91	N/A

Ginkgo Bioworks currently has a consensus price target of $7.00, suggesting a potential downside of 39.44%. Fortrea has a consensus price target of $22.10, suggesting a potential upside of 3.56%. Given Fortrea's stronger consensus rating and higher possible upside, analysts clearly believe Fortrea is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Fortrea	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33

Fortrea has a net margin of -3.18% compared to Ginkgo Bioworks' net margin of -259.96%. Fortrea's return on equity of 10.72% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Fortrea	-3.18%	10.72%	2.17%

Ginkgo Bioworks has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

Summary

Fortrea beats Ginkgo Bioworks on 10 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Ginkgo Bioworks (NYSE:DNA) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Ginkgo Bioworks currently has a consensus price target of $7.00, suggesting a potential downside of 39.44%. Maravai LifeSciences has a consensus price target of $7.38, suggesting a potential upside of 12.60%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Ginkgo Bioworks has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

In the previous week, Ginkgo Bioworks had 7 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.60 beat Ginkgo Bioworks' score of 0.33 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Maravai LifeSciences has a net margin of -37.07% compared to Ginkgo Bioworks' net margin of -259.96%. Maravai LifeSciences' return on equity of -15.70% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Maravai LifeSciences has higher revenue and earnings than Ginkgo Bioworks. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	4.57	-$312.76M	-$5.01	N/A
Maravai LifeSciences	$185.74M	9.16	-$130.77M	-$0.52	N/A

Summary

Maravai LifeSciences beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

BioLife Solutions has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

In the previous week, Ginkgo Bioworks had 7 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 3 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.85 beat Ginkgo Bioworks' score of 0.33 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

BioLife Solutions presently has a consensus target price of $31.38, indicating a potential downside of 18.74%. Ginkgo Bioworks has a consensus target price of $7.00, indicating a potential downside of 39.44%. Given BioLife Solutions' stronger consensus rating and higher possible upside, equities research analysts clearly believe BioLife Solutions is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioLife Solutions has a net margin of 53.29% compared to Ginkgo Bioworks' net margin of -259.96%. BioLife Solutions' return on equity of 2.70% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

BioLife Solutions has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$106.69M	17.71	-$4.59M	$1.16	33.28
Ginkgo Bioworks	$170.15M	4.57	-$312.76M	-$5.01	N/A

Summary

BioLife Solutions beats Ginkgo Bioworks on 12 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alamar Biosciences has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -259.96%. Alamar Biosciences' return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Alamar Biosciences has higher earnings, but lower revenue than Ginkgo Bioworks. Alamar Biosciences is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	23.72	-$29.82M	-$1.96	N/A
Ginkgo Bioworks	$170.15M	4.57	-$312.76M	-$5.01	N/A

Alamar Biosciences currently has a consensus price target of $31.80, indicating a potential upside of 25.34%. Ginkgo Bioworks has a consensus price target of $7.00, indicating a potential downside of 39.44%. Given Alamar Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alamar Biosciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Ginkgo Bioworks had 4 more articles in the media than Alamar Biosciences. MarketBeat recorded 10 mentions for Ginkgo Bioworks and 6 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.41 beat Ginkgo Bioworks' score of 0.33 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ginkgo Bioworks	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Alamar Biosciences beats Ginkgo Bioworks on 10 of the 14 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNA vs. The Competition

Export

Metric	Ginkgo Bioworks	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$788.96M	$10.92B	$7.43B	$23.13B
Dividend Yield	N/A	1.45%	2.52%	3.70%
P/E Ratio	-2.34	32.47	274.96	28.45
Price / Sales	5.96	486.03	608.73	95.40
Price / Cash	N/A	27.31	76.68	36.37
Price / Book	1.34	6.11	10.32	4.72
Net Income	-$312.76M	$56.67B	$3.49B	$1.07B
7 Day Performance	3.00%	-0.39%	-2.54%	-0.07%
1 Month Performance	67.97%	5.00%	-6.87%	-2.64%
1 Year Performance	-25.82%	23.15%	1.81%	5.85%

Ginkgo Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNA Ginkgo Bioworks	1.3437 of 5 stars	$11.72 +1.6%	$7.00 -40.3%	-17.9%	$788.96M	$132.42M	N/A	485	Analyst Forecast Gap Down
TWST Twist Bioscience	1.9889 of 5 stars	$151.86 -5.0%	$135.25 -10.9%	+385.0%	$10.02B	$376.57M	N/A	979	Analyst Forecast Insider Trade Gap Down
FTRE Fortrea	2.2693 of 5 stars	$21.00 +0.8%	$22.10 +5.2%	+123.5%	$1.98B	$2.72B	N/A	14,300	Analyst Downgrade Gap Up
MRVI Maravai LifeSciences	1.3266 of 5 stars	$7.06 -5.1%	$7.38 +4.5%	+102.8%	$1.93B	$185.74M	N/A	415	Gap Up
BLFS BioLife Solutions	2.0862 of 5 stars	$38.61 flat	$31.38 -18.7%	N/A	$1.89B	$106.69M	33.28	155

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, FTRE, MRVI, BLFS, and ALMR

How does Ginkgo Bioworks compare to Twist Bioscience?

Summary

How does Ginkgo Bioworks compare to Fortrea?

Summary

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Summary

How does Ginkgo Bioworks compare to BioLife Solutions?

Summary

How does Ginkgo Bioworks compare to Alamar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, FTRE, MRVI, BLFS, and ALMR

How does Ginkgo Bioworks compare to Twist Bioscience?

Is DNA or TWST more profitable?

Which has more risk and volatility, DNA or TWST?

Do insiders and institutionals hold more shares of DNA or TWST?

Do analysts rate DNA or TWST?

Which has higher valuation and earnings, DNA or TWST?

Does the media prefer DNA or TWST?

Summary

How does Ginkgo Bioworks compare to Fortrea?

Do insiders & institutionals have more ownership in DNA or FTRE?

Does the media refer more to DNA or FTRE?

Which has preferable valuation & earnings, DNA or FTRE?

Do analysts recommend DNA or FTRE?

Is DNA or FTRE more profitable?

Which has more risk and volatility, DNA or FTRE?

Summary

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Do analysts recommend DNA or MRVI?

Which has more volatility & risk, DNA or MRVI?

Does the media favor DNA or MRVI?

Do institutionals & insiders hold more shares of DNA or MRVI?

Is DNA or MRVI more profitable?

Which has preferable earnings & valuation, DNA or MRVI?

Summary

How does Ginkgo Bioworks compare to BioLife Solutions?

Which has more volatility and risk, BLFS or DNA?

Does the media prefer BLFS or DNA?

Do analysts rate BLFS or DNA?

Do insiders & institutionals believe in BLFS or DNA?

Is BLFS or DNA more profitable?

Which has preferable valuation & earnings, BLFS or DNA?

Summary

How does Ginkgo Bioworks compare to Alamar Biosciences?

Do institutionals and insiders believe in ALMR or DNA?

Is ALMR or DNA more profitable?

Which has stronger valuation and earnings, ALMR or DNA?

Do analysts rate ALMR or DNA?

Does the media refer more to ALMR or DNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools